A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer

The proto-oncogene HER2 presents a novel therapeutic target. We report results in 25 patients with HER2+ advanced prostate cancer treated with the bispecific antibody MDX-H210 15 μg m(−2)by intravenous infusion plus GM-CSF 5 μg kg(−1)day(−1)by subcutaneous injection for 4 days repeated weekly for 6...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: James, N D, Atherton, P J, Jones, J, Howie, A J, Tchekmedyian, S, Curnow, R T
Formato: Artigo
Idioma:English
Publicado em: Nature Publishing Group 2001
Assuntos:
Regular Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2364053/
https://ncbi.nlm.nih.gov/pubmed/11461069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2001.1878
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://ncbi.nlm.nih.gov/pmc/articles/PMC2364053/
https://ncbi.nlm.nih.gov/pubmed/11461069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.2001.1878

Registos relacionados